

First detection of mobilized colistin resistance *mcr-I* gene in *Escherichia coli* isolated from livestock and sewage in Iran

F. Nikkhahi¹, S. Robatjazi¹, M. Niazadeh¹, A. Javadi², G. H. Shahbazi¹, P. Aris¹, S. M. Amin Marashi¹ and N. Emam³

1) Medical Microbiology Research Center, 2) Department of Biostatistics, Qazvin University of Medical Sciences, Qazvin and 3) Department of Microbiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Currently, few studies have investigated the mechanisms of resistance to colistin in Iran. The aim of this study was to investigate *mcr*-harbouring *Escherichia coli* dissemination in livestock and sewage in Iran. A total of 115 samples from cows ($n = 38$), chickens ($n = 47$) and urban sewage samples ($n = 30$) were collected. The presence of genes including *mcrI-6* and *ampC* β -lactamase (*bla*_{MOX}, *bla*_{CIT}, *bla*_{DHA}, *bla*_{ACC}, *bla*_{EBC}, *bla*_{FOX}) for colistin-resistant isolates was investigated by multiplex PCR method. Genetic association of colistin-resistant strains was also evaluated by ERIC PCR. Sixty-five isolates were identified as *E. coli*. Meaningless were resistant to colistin. The highest (26.1%) and lowest (3.07%) resistance were shown to ampicillin and meropenem respectively. Among the three colistin-resistant isolates, 2 (66%) were multidrug resistant, with one of them being *mcr-I* positive and the other one positive for DHA *ampC* β -lactamase gene. No *mcr2-6* genes were found. Minimum inhibitory concentration of *mcr*-producing isolate was 4 mg/L by microbroth dilution. This study reports, first the detection of *mcr-I* in *E. coli* from farm animals in Iran, a finding that is indicative of a global distribution of this plasmidic element and threatening the use of colistin as a last resort antibiotic. No clonal relationship was observed between the colistin-resistant *E. coli* isolates by ERIC-PCR. Monitoring the presence of these strains in animal sources help as to controlling the spread of resistance genes from animal to human is vital.

© 2021 The Authors. Published by Elsevier Ltd.

Keywords: Colistin resistance, *Escherichia coli*, livestock, *mcr-I*

Original Submission: 13 October 2020; **Revised Submission:** 17 February 2021; **Accepted:** 4 March 2021

Article published online: 18 March 2021

Corresponding author: F. Nikkhahi, Medical Microbiology Research Center, Qazvin University of Medical Sciences, PO Box 34199, 15315, Qazvin, Iran.
E-mail: Farhadnikkhahi@gmail.com

Introduction

The increasing prevalence of antibiotic resistance is one of the global health threats in the 21st century [1]. *Escherichia coli* (*E. coli*) is recognized as one of the major causes of nosocomial infections [1,2], acting as a reservoir of antimicrobial resistance genes (AMRs). Polymyxins, including polymyxin B and colistin, are the latest agents for the treatment of infections related to multidrug resistant gram negative bacteria (MDR-GNB) [2]. These agents primarily bind to the bacterial surface and reduce its

integrity, increase its permeability and ultimately lead to the death of bacteria [3]. However, the use of colistin has been limited for treatment considering its nephrotoxic and neurotoxic effects [4]. By 2015, mutations in two-component regulatory systems, including *PmrB*, *PmrA*, *PhoP*, *PhoQ* and *MgrB*, were the only resistance mechanisms to colistin [5]. The mobilized colistin resistance (*mcr*) gene, conferring plasmid-mediated resistance to colistin, was first detected in China [2,3]. So far, ten different plasmid-mediated colistin resistance genes have been reported in the *Enterobacteriaceae* family. *E. coli* studies have particularly demonstrated that poultry and livestock can potentially carry isolates containing *mcr* genes; therefore, they can transfer drug-resistant bacteria to humans. Colistin is widely used in veterinary medicine to treat gastroenteritis in food-producing animals, especially pigs and poultry [6].

Despite the increasing prevalence of *mcr* plasmid-mediated colistin resistance among clinical isolates and the risk of